儿童免疫性血小板减少症中艾曲泊帕治疗失败后换用阿伐曲泊帕的结局:中国真实世界研究
该研究回顾性评估了2021年7月至2022年5月北京儿童医院血液肿瘤中心11例慢性免疫性血小板减少症(cITP)患儿,因艾曲泊帕(ELT)治疗失败换用阿伐曲泊帕(AVA)的结局。AVA治疗期间总体缓解率和完全缓解率分别为81.8%(9/11)和54.6%(6/11),中位血小板计数从ELT时的7(范围2-33)×10^9/L显著升至74(15-387)×10^9/L(p=0.007)。结论认为AVA在经重度治疗的儿童cITP人群中对ELT后有效。
要点
- 儿童cITP中ELT失败后换用AVA,总体缓解率81.8%(9/11),完全缓解率54.6%(6/11)。
- 中位血小板计数从ELT时7(2-33)×10^9/L升至AVA时74(15-387)×10^9/L(p=0.007)。
- 7/11例(63.6%)使用合并用药,在AVA启动后3-6个月内逐渐停用。
核心结论
- 在经重度治疗的儿童cITP人群中,ELT后换用AVA有效,即使在既往TPO-RA应答不足者中也有高缓解率。
研究设计与样本
- 回顾性研究,纳入2021年7月至2022年5月北京儿童医院血液肿瘤中心因治疗失败从ELT换用AVA的慢性免疫性血小板减少症(cITP)患儿11例(男7例、女4例),中位年龄8.3(范围3.8-15.3)岁。
主要发现
- AVA治疗期间总体缓解率为81.8%(9/11),完全缓解(血小板计数≥100×10^9/L)率为54.6%(6/11)。
- 中位血小板计数从ELT时7(范围2-33)×10^9/L升至AVA时74(范围15-387)×10^9/L,p=0.007。
- 达到血小板计数≥30×10^9/L的中位时间为18(范围3-120)天。
- 7/11例(63.6%)使用合并用药,在AVA启动后3-6个月内逐渐停用。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Immune thrombocytopenia (ITP) is an autoimmune bleeding disorder characterized by isolated thrombocytopenia and a haemorrhagic risk. Thrombopoietin receptor agonists (TPO-RAs) are highly effective for ITP and are widely used to treat patients with steroid treatment failure or dependency. However, although treatment response to TPO-RAs may differ according to the type, the potential impact of switching from eltrombopag (ELT) to avatrombopag (AVA) with respect to efficacy or tolerance in children remains unknown. This study aimed to evaluate the outcomes of switching from ELT to AVA in paediatric patients with ITP. We retrospectively evaluated children with chronic immune thrombocytopenia (cITP) switched from ELT to AVA owing to treatment failure at the Hematology-Oncology Center of Beijing Children's Hospital between July 2021 and May 2022. Overall, 11 children (seven and four boys and girls respectively) with a median age of 8.3 (range: 3.8-15.3) years were included. The overall response and complete response (platelet [PLT] count ≥100 × 109 /L) rates during AVA treatment were 81.8% (9/11) and 54.6% (6/11) respectively. The median PLT count was significantly increased from ELT to AVA (7 [range: 2-33] × 109 /L vs. 74 [15-387] × 109 /L; p = 0.007). The median time to PLT count ≥30 × 109 /L was 18 (range: 3-120) days. Overall, 7/11 patients (63.6%) used concomitant medications, and concomitant medication use was gradually discontinued within 3-6 months after AVA initiation. In conclusion, AVA after ELT is effective in the heavily pretreated paediatric cITP population, with high response rates even in those with an inadequate response to a prior TPO-RA.
引用
- Cheng X, Wang Z, Dong S, et al. Outcomes of switching to avatrombopag following treatment failure with eltrombopag in paediatric immune thrombocytopenia: A real-world study in China. Br J Haematol. 2023. PMID: 37188335. doi:10.1111/bjh.18864
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。